01 August 2022 | Features
Revolutionizing pathology through robotics and advanced AI
Founders- Dr Tathagato Rai Dastidar, Rohit Kumar Pandey and Apurv Anand
Total team strength- 70
Total funds raised- Rs 323 crore
Investors- Sachin Bansal, Binny Bansal, Accel, Chiratae, Endiya, Pi, Axilor, Venture Highway, Trusted Insights.
Revenue generated since inception- NA
"We are targeting an annual revenue of $40M–$50M within the next 5 years, with a 70%+ gross margin, and ~35% operating margin. We are targeting 5000+ installations across the world in the next 5 years. We want to remain focused on our primary goal – automating manual microscopy. That said, we will create new products along multiple lines: Supporting multiple more tests through the AI100 hardware, like histopathology, microbiology, pap smears, etc.; Bringing in more automation to the hardware to make it appealing to the very large labs segment, which require very high throughput; Targeting the clinics, PHCs, etc. with a point of care device for blood and urine testing. This will significantly expand the market beyond traditional clinical laboratories and take us to scenarios and places where no critical disease screening is not possible today.
There is an overall lack of deep tech ecosystem in India. This needs to change if India has to emerge as a deep tech hub too, in addition to being a consumer tech superpower."
- Dr Tathagato Rai Dastidar, Founder & CEO, SigTuple, Bengaluru